It’s a $1.6 trillion question: Which impact investment practices and characteristics truly generate the positive outcomes that investors and stakeholders want to see? With a 21 percent compound annual ...

Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab. Objectives: ...

Managing system risk is paramount for organizations to protect their data and ensure operational continuity. Security Impact Analysis (SIA) is a critical component of this process, offering a ...

The introduction of lebrikizumab, a novel monoclonal antibody targeting interleukin-13 for severe atopic dermatitis (AD), was associated with cost savings of approximately €3.3 million over 3 years ...